Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| XRTX | 424B4 | bearish | 7/10 | XORTX Therapeutics priced a $5.0M registered direct offering of 183,577 common shares at $1.88/share and 2,475,997 pre-f | May 15, 2026 |
| TNXP | 8-K | bullish | 6/10 | Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody to prevent Lyme disease, at | May 15, 2026 |
| ACIU | 6-K | neutral | 3/10 | AC Immune SA published its 2026 Annual General Meeting invitation, detailing the CEO transition from Andrea Pfeifer to i | May 15, 2026 |
| EDSA | 8-K | neutral | 2/10 | CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested RSUs instead of cas | May 15, 2026 |
| TERN | 15-12G | bearish | 8/10 | Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective May 15, 2026. | May 15, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The company highlighted a | May 15, 2026 |
| SXTP | PRESS-RELEASE | bearish | 6/10 | Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, signif | May 15, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine's CEO participated in an invite-only federal policy summit at the National Press Club, convened by th | May 15, 2026 |
| MBRX | PRESS-RELEASE | bearish | 6/10 | Moleculin Biotech reported Q1 2026 net loss of $12.8M ($3.54/share) vs $5.9M loss a year ago, with zero revenue. The EPS | May 15, 2026 |
| MENS | PRESS-RELEASE | neutral | 2/10 | Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no | May 15, 2026 |
| TIL | 8-K | neutral | 4/10 | Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a pre-revenue biotech the abso | May 15, 2026 |
| MBRX | 8-K | mixed | 6/10 | Moleculin reported Q1 2026 results with no revenue, a net loss of $(14.6M) or $(3.54) per share, and $10.3M cash (into Q | May 15, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics entered into warrant exercise agreements to raise ~$1M in gross proceeds, issuing new Series C and | May 15, 2026 |
| PULM | 8-K | neutral | 4/10 | Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood a | May 15, 2026 |
| BCDA | 8-K | mixed | 6/10 | BioCardia reported Q1 2026 financial results with a net loss of $2.3M ($0.21 per share), narrower than the $2.7M loss ($ | May 15, 2026 |
| INKT | 8-K | neutral | 5/10 | MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$ | May 15, 2026 |
| ATYR | 8-K | bullish | 5/10 | aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and ended the quarter with | May 15, 2026 |
| GALT | PRESS-RELEASE | bullish | 6/10 | Galectin Therapeutics reported Q1 2026 EPS of -$0.08, missing consensus of -$0.06 (-33.3% miss), but highlighted positiv | May 15, 2026 |
| BCDA | PRESS-RELEASE | mixed | 6/10 | BioCardia reported Q1 2026 EPS of -$0.21, missing consensus of -$0.17 by 23.5%, while revenue remained zero. However, th | May 15, 2026 |
| COCP | PRESS-RELEASE | neutral | 5/10 | Cocrystal Pharma reported Q1 2026 EPS of -$0.17, missing consensus of -$0.15 by 13.3%, and recognized $225k in grant rev | May 15, 2026 |
| ATYR | PRESS-RELEASE | neutral | 5/10 | aTyr Pharma reported Q1 2026 EPS of -$0.14, a 3.9% beat vs consensus of -$0.15, on no revenue. The company announced pla | May 15, 2026 |
| ENVB | 8-K | neutral | 4/10 | Enveric Biosciences reported Q1 2026 results with a net loss of $1.6M ($1.08 per share) vs $2.2M in Q1 2025. Cash increa | May 15, 2026 |
| CGON | PRESS-RELEASE | bullish | 6/10 | CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at | May 15, 2026 |
| INDP | 8-K | bearish | 7/10 | Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in | May 15, 2026 |
| GDTC | 6-K | bullish | 5/10 | Chairman and Director Choo Chee Kong acquired 112,000 ordinary shares in a private purchase on May 13, 2026, and stated | May 15, 2026 |
| GALT | 8-K | neutral | 5/10 | Galectin Therapeutics reported Q1 2026 results with a net loss of $5.1M ($0.08/share), narrower than the $9.6M loss in Q | May 15, 2026 |
| IMRX | PRESS-RELEASE | bullish | 7/10 | Immuneering reported Q1 2026 EPS of -$0.21, beating consensus of -$0.25 by 16%, with no revenue. The key catalyst is upc | May 15, 2026 |
| SNSE | 8-K | neutral | 4/10 | Sensei Biotherapeutics reported Q1 2026 results showing a net loss of $170.2M ($131.45/share), primarily driven by a $13 | May 15, 2026 |
| INKT | PRESS-RELEASE | bullish | 6/10 | MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M f | May 15, 2026 |
| PVLA | PRESS-RELEASE | bullish | 7/10 | Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleed | May 15, 2026 |